Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
JANX Quote, Financials, Valuation and Earnings
Last price:
$14.25
Seasonality move
:
45.56%
Day range:
$13.93 - $14.28
52-week range:
$13.76 - $61.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
86.41x
P/B ratio:
0.88x
Volume:
1.9M
Avg. volume:
2.6M
1-year change:
-74.17%
Market cap:
$857.1M
Revenue:
$10.6M
EPS (TTM):
-$1.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$850K | -$0.71 | 599.64% | -80.26% | $65.12 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$188.4M | -$0.50 | -32.54% | -80.29% | $87.99 |
|
LLY
Eli Lilly & Co.
|
$17B | $7.46 | 31.31% | 54.16% | $1,093.22 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$306.1M | -$0.72 | 200.72% | -82.86% | $603.47 |
|
MNKD
MannKind Corp.
|
$110.7M | $0.07 | 30.4% | 17.65% | $9.61 |
|
STOK
Stoke Therapeutics, Inc.
|
$3.9M | -$0.78 | -77.5% | -289.69% | $34.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$14.25 | $65.12 | $857.1M | -- | $0.00 | 0% | 86.41x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$79.93 | $87.99 | $12.9B | -- | $0.00 | 0% | 13.61x |
|
LLY
Eli Lilly & Co.
|
$1,077.75 | $1,093.22 | $964.6B | 53.30x | $1.50 | 0.56% | 16.54x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$598.91 | $603.47 | $13.6B | -- | $0.00 | 0% | 17.93x |
|
MNKD
MannKind Corp.
|
$5.79 | $9.61 | $1.8B | 61.47x | $0.00 | 0% | 5.70x |
|
STOK
Stoke Therapeutics, Inc.
|
$31.92 | $34.25 | $1.8B | 48.37x | $0.00 | 0% | 9.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
2.27% | -0.738 | 1.54% | 35.54x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
|
MNKD
MannKind Corp.
|
124.56% | 0.023 | 13.7% | 2.54x |
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.663 | 0.37% | 6.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$9.5M | -$35.3M | -10.68% | -10.94% | -352.51% | -$12.9M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
Janux Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns JANX or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -82.06%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About JANX or IONS?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 356.97%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 10.08%. Given that Janux Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is JANX or IONS More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock JANX or IONS?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or IONS?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 86.41x versus 13.61x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M IONSIonis Pharmaceuticals, Inc.13.61x -- $156.7M -$128.6M
-
Which has Higher Returns JANX or LLY?
Eli Lilly & Co. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 31.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About JANX or LLY?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 356.97%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Janux Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Janux Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 LLYEli Lilly & Co.18 7 0 -
Is JANX or LLY More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock JANX or LLY?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JANX or LLY?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 86.41x versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M LLYEli Lilly & Co.16.54x 53.30x $17.6B $5.6B
-
Which has Higher Returns JANX or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -39.75%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About JANX or MDGL?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 356.97%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.76%. Given that Janux Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is JANX or MDGL More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock JANX or MDGL?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or MDGL?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 86.41x versus 17.93x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M MDGLMadrigal Pharmaceuticals, Inc.17.93x -- $287.3M -$114.2M
-
Which has Higher Returns JANX or MNKD?
MannKind Corp. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 9.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About JANX or MNKD?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 356.97%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 66%. Given that Janux Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Janux Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 MNKDMannKind Corp.8 0 0 -
Is JANX or MNKD More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.
-
Which is a Better Dividend Stock JANX or MNKD?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or MNKD?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than MannKind Corp.'s net income of $8M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 61.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 86.41x versus 5.70x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M MNKDMannKind Corp.5.70x 61.47x $82.1M $8M
-
Which has Higher Returns JANX or STOK?
Stoke Therapeutics, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -360.68%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M -
What do Analysts Say About JANX or STOK?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 356.97%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $34.25 which suggests that it could grow by 7.3%. Given that Janux Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 STOKStoke Therapeutics, Inc.9 0 0 -
Is JANX or STOK More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.
-
Which is a Better Dividend Stock JANX or STOK?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or STOK?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 48.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 86.41x versus 9.06x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.86.41x -- $10M -$24.3M STOKStoke Therapeutics, Inc.9.06x 48.37x $10.6M -$38.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
